Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -33.8% | 77.6% | 1,357.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -429.9% | -305.8% | -591.9% | -7,292.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -383.2% | -288.2% | -566.3% | -7,681.6% |
| EPS Diluted | -1.58 | -2.34 | -2.62 | -2.78 |
| % Growth | 32.5% | 10.7% | 5.8% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |